HC Wainwright Begins Coverage on Innate Pharma (IPHYF)
HC Wainwright started coverage on shares of Innate Pharma (NASDAQ:IPHYF) in a research note published on Wednesday, MarketBeat reports. The firm issued a buy rating on the stock.
Separately, Zacks Investment Research upgraded Innate Pharma from a sell rating to a hold rating in a research report on Tuesday, May 9th.
Shares of Innate Pharma (NASDAQ IPHYF) remained flat at $12.96 on Wednesday. Innate Pharma has a 52-week low of $10.72 and a 52-week high of $16.55. The firm has a 50-day moving average price of $12.56 and a 200 day moving average price of $12.41. The firm has a market cap of $699.74 million and a PE ratio of 48.18.
Receive News & Stock Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related stocks with our FREE daily email newsletter.